vimarsana.com

HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.73) […]

Related Keywords

Aadi Bioscience ,Neil Desai ,Decheng Capital ,Securities Exchange Commission ,Td Asset Management Inc ,Marquette Asset Management ,Aadi Bioscience Inc ,Free Report ,Get Free Report ,Chairman Neil Desai ,Exchange Commission ,Asset Management ,Management Inc ,Aadi Bioscience Daily ,Nasdaq Aadi ,Maadi ,Medical ,Reiterated Rating ,Hc Wainwright ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.